Dan Strack
Contributor since: 2013
Latest Articles
Audentes Therapeutics: Key Program Updates
Audentes Therapeutics' Upcoming Catalysts
Intellia Therapeutics: An In Vivo Advantage
REGENXBIO: An Underappreciated Leader In Gene Editing
IMAX To Return To Profitability
Disney Is A Buy On Improving Free Cash Flow
IMAX May Surprise Investors
IMAX Has Near And Long-Term Growth Catalysts
Five Prime Therapeutics At An Attractive Entry Level
Wayfair Has No Path To Profitability
Stumbling Blocks Loom For Domino's
IBM Should Buy Palo Alto Networks
ContraFect: More Dilution In Store
Gilead And Intellia Therapeutics A Natural Fit
NewLink Genetics Unfairly Punished
Under Armour: Now A Long-Term Buy?
Intellia Therapeutics: Game-Changing Technology Trading At Steep Discount
Five Prime Therapeutics Could Be The Ace Up The Sleeve Of Bristol-Myers Squibb
2016 Investment Themes And Top 7 Picks
ContraFect Is A Speculative Buy On Positive News From Phase 1 Trials
Cummins: Where's The Bottom?
AT&T Is Once Again A Buy
Can Amazon Grow Into Its Valuation?
AMC Entertainment Is Ready To Bounce
Harman: An Under-Appreciated Growth Story
Attractive Risk/Reward Profile At DSW
Under Armour's Potential Is Huge, But Is It A Buy?
Harley-Davidson Is A Long-Term Buy On Recent Pullback
Will Slowing Growth In Same-Store Sales Be The New Norm For Chipotle?
Can Garmin Stop The Bleeding?
Wal-Mart Just Told You It's A Value Trap
GoPro: When A Growth Stock Became A Value Stock